DexCom upgraded to Buy from Neutral at Redburn Atlantic

Redburn Atlantic upgraded DexCom (DXCM) to Buy from Neutral with a price target of $115, up from $85. The company is positioned to benefit from structural growth in the continuous glucose monitoring market, supporting 16% annual revenue growth through fiscal 2027 as it expands into the “underpenetrated” type 2 non-insulin segment, the analyst tells investors in a research note. The firm says its confidence is enhanced by DexCom’s next-generation G8 sensor, while its revenue mix has stabilized with the U.S. pharmacy transition largely concluded. Dexcom’s valuation is yet to reflect its improved earnings growth outlook, contends Redburn.